Cyclooxygenase-2 polymorphisms and susceptibility to colorectal cancer: A meta-analysis

Yonsei Medical Journal

Volumn 54, Issue 6, 2013, Pages 1353-1361

  Wang, Jun ^a   Guo, Xufeng ^a   Zhang, Jixiang ^a   Song, Jia ^a   Ji, Mengyao ^a   Yu, Shijie ^a   Wang, Jing ^a   Cao, Zhuo ^a   Dong, Weiguo ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Cyclooxygenase 2; Meta analysis; Polymorphism

Indexed keywords

CYCLOOXYGENASE 2;

ALLELE; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; DATA EXTRACTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; PUBLISHING; QUALITY CONTROL; SENSITIVITY ANALYSIS;

COLORECTAL CANCER; CYCLOOXYGENASE-2; META-ANALYSIS; POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC;

EID: 84886474869     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.6.1353     Document Type: Article

References (38)

1. Hutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, et al. Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res 2012;72:2036-44.
2. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003;7:207-22.
3. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27.
4. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol 2012;47:97-106.
5. van Rees BP, Ristimäki A. Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 2001;36:897-903.
6. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
7. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 2001;299:468-76.
8. Wiesner GL, Platzer P, Buxbaum S, Lewis S, MacMillen M, Olechnowicz J, et al. Testing for colon neoplasia susceptibility variants at the human COX2 locus. J Natl Cancer Inst 2001;93: 635-9.
9. Hamajima N, Takezaki T, Matsuo K, Saito T, Inoue M, Hirai T, et al. Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer. Asian Pac J Cancer Prev 2001;2:57-62.
10. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004;91:339-43.
11. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 2004;90:1760-4.
12. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-li-poxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007;28:1197-201.
13. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, et al. Cyclo-oxygenase 2 polymorphism and colorectal cancer:-765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol 2008;14:1785-9.
14. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, González-Aguilera JJ, Fernández-Peralta AM. Effect of COX2-765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 2009;20:1421-9.
15. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol 2009;15: 2240-4.
16. Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, Peters WH. COX-2 polymorphisms-765G-->C and-1195A-->G and colorectal cancer risk. World J Gastroenterol 2009;15:4561-5.
17. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 2009;9:407.
18. Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 2010;22:607-13.
19. Daraei A, Salehi R, Mohamadhashem F. PTGS2 (COX2)-765G>C gene polymorphism and risk of sporadic colorectal can-cer in Iranian population. Mol Biol Rep 2012;39:5219-24.
20. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006;119:297-303.
21. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002;11:1305-15.
22. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004;25: 2467-72.
23. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, et al. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 2006;17:257-66.
24. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
26. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48.
27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629-34.
29. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005;128:1445-61.
30. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000;7:1163-70.
31. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78.
32. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
33. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1: 11-21.
34. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygen-ase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22: 131-6.
35. Dixon DA. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res 2003;37:52-71.
36. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
37. Gou Q, Liu CH, Ben-Av P, Hla T. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclo-oxygenase-2 mRNA by mutagenesis of the 3'-untranslated region. Biochem Biophys Res Commun 1998;242:508-12.
38. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. J Biol Chem 2000;275:11750-7.